¹⁵³Samarium-EDTMP et contrôle de la douleur liée aux métastases osseuses des cancers bronchiques

Introduction: The treatment of bone metastasis from lung cancer is palliative in nature with elimination of pain being the primary goal. Management is based on pharmacological methods (steroids, morphine, and pamidronate) and radiotherapy. However, other treatments have been developed including the systemic radiopharmaceutical ¹⁵³Sm-EDTMP. Case Reports: We report data from 6 lung cancer patients with bone metastases treated with ¹⁵³Sm-EDTMP. Demographic and therapeutic data, pain evaluation by visual analogue scale (VAS) and change in opioid analgesia requirements (expressed as intravenous morphine equivalent) as well as survival were studied. Pain associated with bone metastasis (median VAS = 8 [7-9], median morphine dose = 167 mg [100-800 mg]) did not significantly improve (median VAS after ¹⁵³Sm-EDTMP = 8.5 [5-10], median morphine dose after ¹⁵³Sm-EDTMP = 185 mg [30-2 200 mg]) in this group of patients. Conclusion: Our results combined with current data in the literature concerning the use of this treatment in the treatment of bone pain associated with metastatic lung cancer suggest that at present its use cannot be recommended outside the context of clinical of clinical trials.